Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
This Helps Clinicians Tailor Diabetes Treatment
Diabetes Care; ePub 2017 Oct 11; Herman, et al
Knowing a person’s risk of progressing to diabetes and regressing to normal glucose regulation (NGR) allows clinicians to tailor treatment, researchers concluded after conducting an analysis Diabetes Prevention Program (DPP) data. Investigators used the 19 clinical variables measured at DPP baseline to assess diabetes progression and NGR regression at 3 years in adherent participants randomized to lifestyle, metformin, and placebo cohorts. 11 variables predicted diabetes progression, and 6 projected NGR regression. Compared with placebo participants at the lowest risk of developing diabetes:
- Patients in the lifestyle group at the lowest risk had an 8% reduced risk of developing diabetes.
- They were 35% more likely to revert to NGR.
- In the metformin group with the lowest risk, these percentages were 0% and 17%, respectively.
Compared with placebo participants at the highest risk of developing diabetes:
- Progression and regression percentages in the high-risk lifestyle group were 39% and 24%, respectively.
- In the high-risk metformin contingent, these percentages were 25% and 11%, respectively.
Herman W, Pan Q, Edelstein S, et al. Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation. [Published online ahead of print October 11, 2017]. Diabetes Care. doi:10.2337/dc17-1116.